Advances in ALK Inhibition in Non-Small Cell Lung Cancer
Oct 14, 2025 · Crizotinib, which targets both ALK and MET, has shown clinical benefit in patients who develop MET amplification following alectinib treatment, with observed tumor responses after …
Real-world treatment sequencing and effectiveness of second- and …
Sep 1, 2024 · With multiple targeted therapies approved for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), it is increasingly important to understand outcomes …
Treatment of metastatic ALK-positive non-small cell lung cancer ...
May 9, 2025 · Introduction: Anaplastic lymphoma kinase (ALK) inhibitors (ALKi) are the standard treatment for metastatic, ALK-positive non-small cell lung cancer (NSCLC). Second- and third …
Lorbrena Effective as Initial Treatment of ALK-Positive NSCLC
Jul 10, 2024 · A major question for both patients and health care providers, Dr. Zhao said, is whether to use lorlatinib or another ALK inhibitor, such as alectinib, as initial treatment for advanced ALK …
STS 2025 Best of Lung Cancer Science
The Targeted Era: Cementing ALK Inhibitors in Early-Stage Care • Drs. Donington and Bestvina reviewed updated data from ALINA and ELEVATE, underscoring how ALK inhibitors are redefining …
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
Apr 10, 2024 · Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the efficacy and safety of …
Patient and oncologist preferences for ALK+ advanced non-small cell ...
Nov 21, 2025 · PURPOSE: Next-generation anaplastic lymphoma kinase (ALK)-targeting tyrosine kinase inhibitors (TKIs) are standard first-line (1L) treatments for ALK+ advanced non-small cell lung cancer …
Frontline Treatment Decisions in ALK+ NSCLC - CancerNetwork
Jul 25, 2025 · The treatment landscape for ALK-positive advanced non–small cell lung cancer (NSCLC) has been revolutionized by the availability of highly effective second- and third-generation ALK …
Identifying optimal ALK inhibitors in first- and second-line treatment ...
Feb 8, 2024 · Objectives To compare the efficacy, safety and effects on quality of life of different ALK-inhibitors for global and Asian patients with advanced ALK-positive non-small-cell lung cancer …
ALK+ NSCLC Treatment Guidelines
Use of ALK TKIs is effective for treatment of patients with ALK+ NSCLC and CNS involvement, and evidence supports alectinib, brigatinib or ceritinib in this setting as first-line therapy.